2025 China biotech survey report
Refining the formula for global ambition
What is the report about?
In 2023 ICON Biotech and Citeline conducted a survey of global biotech leaders to understand the challenges they faced. That same year China matched the US for clinical trial volume. Today, China conducts a quarter of all clinical trials and drug development, and has close to 1,500 new drugs in development, overtaking US drug development. The rise of biotech in China is the result of decades of government planning, favorable policies, continued regulatory reform, strategic partnerships and an educated, productive workforce.
Download 2025 China biotech survey report today and get insights into what biotech is expecting in 2026.
In 2025, as ICON Biotech repeated the global survey, 100 biotech leaders in China were surveyed in parallel. In common with their colleagues worldwide, funding remains challenging and dealing with increasingly complex drug development and regulations further complicated matters. In spite of the challenges, 95% of survey respondents are confident about achieving their next investment milestone and 94% believe that their products will succeed.
How has China gained importance in biotech sector?
China’s biotech sector continues to expand, contributing 23% of the world’s innovative drug pipeline. ICON Biotech surveyed 100 biotech leaders in China to learn about the risks, challenges and opportunities in this significant biotech region. Get your copy of this new report for the latest insights into this biotech powerhouse including:
- Funding challenges & opportunities
- Therapeutic area activities
- Modalities
- VC commentary
- How China has gained prominence
- Potential opportunities
- Securing the talent pipeline
- Biotech sentiment
Interested in the global perspective?
Download the 2025 Global biotech sector survey today.